Citations

Showing 10 of 108094 citations.

Impact of COVID-19 on diagnosis of primary pulmonary coccidioidomycosis
Ashcherkin, N., Huff, Daniel A., Vikram, Holenarasipur R. , Ampel, Neil M. , Blair, Janis E. , Gupta, Simran , Vikram, Holenarasipur R. , Huff, Daniel , Fischer, Karen M.

Mayo Clinic

Medicine | September 2, 2022 | Volume: 101 | Issue: 35 | Pages: e30361

10.1097/md.0000000000030361 | PMID 36107584 Get It

The COVID-19 pandemic has disrupted medical care worldwide and caused delays in care for many illnesses and procedures unrelated to COVID-19; however, less clear is how it may have affected diagnosis of conditions that present with similar symptoms, such as primary pulmonary coccidioidomycosis (PPC). We conducted an observational cohort study of patients diagnosed with PPC between March 1 and December 1 in 2 years: 2019 (before COVID-19) and in 2020 (after COVID-19) to compare the time from symptom onset to PPC diagnosis. Relevant demographic and clinical variables were collected, and statistical analyses were performed with the χ 2 test, Wilcoxon rank sum test, and Cox proportional hazards regression analysis. During 2019, 83 patients were diagnosed with PPC. During 2020, 113 patients were diagnosed with PPC. For both groups, the median time from symptom onset to diagnosis of PPC was 14 days (P = .13). No significant differences in time to diagnosis existed between the 2 years for location of diagnosis (outpatient clinic, emergency department, or in hospital), for computed tomographic imaging performed before diagnosis, or for number of COVID-19 tests received before PPC diagnosis. In addition, there were no differences in the 2 years between the total number of clinical visits before diagnosis. However, patients in the post-COVID-19 group who had fever were diagnosed with PPC earlier than those without fever (hazard ratio, 1.77; 95% confidence interval, 1.15–2.73; P = .01). Contrary to what we expected, no significant delay in diagnosis of PPC occurred during the COVID-19 pandemic.
Assessment of Clinician Diagnostic Concordance With Video Telemedicine in the Integrated Multispecialty Practice at Mayo Clinic During the Beginning of COVID-19 Pandemic From March to June 2020
Butterfield, Richard , Haglin, Jack M. , Haddad, Tufia C. , Yiannias, James A. , Colby, Christopher E. , TerKonda, Sarvam P. , Ommen, Steve R. , Bushman, Matthew S., Lokken, Troy G., Blegen, Rebecca N., Hoff, Mekenzie D., Coffey, Jordan , Anthony, Greg S., Zhang, Nan , Anaya, Stephanie, Arbon, Jake, Berry, Nicholas, Bhargav, Adip, Breslin, Lauren , Cummings, Gabrielle , Ekstein, Samuel F. , Fung, Cecilia, Gorman, Benjamin G. , Harrington, M., Hwang, James , Kirollos, Monica, Lang, Meg, Lopdrup, Rachel , Malekian, Sheila, Patel, Parth , Roth, Alex, Saifuddin, Hiba, Sykora, Daniel, VanLith, Caitlin J. , Wilder, Samantha, Wu, Samuel S. , Pines, Andrew, Yiannias, James, Coffey, Jordan D, Coffey, Jordan D , Demaerschalk, Bart M. , Pines, Andrew R. , Bushman, Matthew S, Bhargav, Adip G., Jarvis, Tyler, Pollock, Jordan Riley , Shimshak, Serena , Wilder, Samantha

Mayo Clinic

JAMA Network Open | September 2, 2022 | Volume: 5 | Issue: 9 | Pages: e2229958

10.1001/jamanetworkopen.2022.29958 | PMID 36053531 Get It

ImportanceThere was a shift in patient volume from in-person to video telemedicine visits during the COVID-19 pandemic.ObjectiveTo determine the concordance of provisional diagnoses established at a video telemedicine visit with diagnoses established at an in-person visit for patients presenting with a new clinical problem.Design, Setting, and ParticipantsThis is a diagnostic study of patients who underwent a video telemedicine consultation followed by an in-person outpatient visit for the same clinical problem in the same specialty within a 90-day window. The provisional diagnosis made during the video telemedicine visit was compared with the reference standard diagnosis by 2 blinded, independent medical reviewers. A multivariate logistic regression model was used to determine factors significantly related to diagnostic concordance. The study was conducted at a large academic integrated multispecialty health care institution (Mayo Clinic locations in Rochester, Minnesota; Scottsdale and Phoenix, Arizona; and Jacksonville, Florida; and Mayo Clinic Health System locations in Iowa, Wisconsin, and Minnesota) between March 24 and June 24, 2020. Participants included Mayo Clinic patients residing in the US without age restriction. Data analysis was performed from December 2020 to June 2021.ExposuresNew clinical problem assessed via video telemedicine visit to home using Zoom Care Anyplace integrated into Epic.Main Outcomes and MeasuresConcordance of provisional diagnoses established over video telemedicine visits compared against a reference standard diagnosis.ResultsThere were 2393 participants in the analysis. The median (IQR) age of patients was 53 (37-64) years; 1381 (57.7%) identified as female, and 1012 (42.3%) identified as male. Overall, the provisional diagnosis established over video telemedicine visit was concordant with the in-person reference standard diagnosis in 2080 of 2393 cases (86.9%; 95% CI, 85.6%-88.3%). Diagnostic concordance by International Statistical Classification of Diseases and Related Health Problems, Tenth Revision chapter ranged from 64.7% (95% CI, 42.0%-87.4%) for diseases of the ear and mastoid process to 96.8% (95% CI, 94.7%-98.8%) for neoplasms. Diagnostic concordance by medical specialty ranged from 77.3% (95% CI, 64.9%-89.7%) for otorhinolaryngology to 96.0% (92.1%-99.8%) for psychiatry. Specialty care was found to be significantly more likely than primary care to result in video telemedicine diagnoses concordant with a subsequent in-person visit (odds ratio, 1.69; 95% CI, 1.24-2.30; P < .001).Conclusions and RelevanceThis diagnostic study of video telemedicine visits yielded a high degree of diagnostic concordance compared with in-person visits for most new clinical concerns. Some specific clinical circumstances over video telemedicine were associated with a lower diagnostic concordance, and these patients may benefit from timely in-person follow-up.
Development and validation of a new disease-specific quality of life instrument for sporadic vestibular schwannoma: the Mayo Clinic Vestibular Schwannoma Quality of Life Index
Carlson, Matthew L. , Lohse, Christine M. , Link, Michael J. , Tombers, Nicole M. , McCaslin, Devin L. , Saoji, Aniket A. , Hutchins, Melanie, Yost, Kathleen J.

Mayo Clinic

Journal of Neurosurgery | September 2, 2022 | Volume: 138 | Issue: 4 | Pages: 981-991

10.3171/2022.7.jns221104 | PMID 36057121 Get It

OBJECTIVE Facial nerve function, hearing preservation, and tumor control have been the primary benchmarks used to assess vestibular schwannoma (VS) outcomes. Acknowledging the frequent discrepancy between what physicians prioritize and what patients value, there has been increasing prioritization of patient-reported outcome measures when evaluating the impact of VS diagnosis and its treatment. Motivated by reported limitations of prior instruments used to assess quality of life (QOL) in patients with VS, the authors describe the development and validation of a new disease-specific QOL measure: the Vestibular Schwannoma Quality of Life (VSQOL) Index. METHODS The content development phase comprised identification of clinically important domains and prioritization of feelings or concerns individuals with VS may have. The validation phase encompassed determining how items were grouped into domains and eliminating redundant items. Both phases leveraged data from cross-sectional and longitudinal surveys, expertise from a multidisciplinary working group, and patients with a broad range of experiences with VS (n = 42 during content development and n = 263 during validation). Domain scores from the new instrument were assessed for reliability and correlation with other measures of similar constructs. RESULTS The VSQOL Index consists of 40 items that evaluate the impact of VS diagnosis and its management on QOL, treatment satisfaction, and employment and is estimated to take 8–10 minutes to complete. Domain scores range from 0 (worst) to 100 (best) and demonstrate excellent psychometric properties, including content, construct, and convergent validity and both internal consistency (Cronbach’s alphas 0.83 to 0.91) and test-retest reliability (reliability coefficients 0.86 to 0.96). CONCLUSIONS The VSQOL Index is a valid and reliable measure that overcomes several limitations of prior instruments, including omission or underrepresentation of domains that frequently impact well-being, such as pain, cognition, satisfaction or regret surrounding treatment decisions, and occupational limitations, to comprehensively evaluate the impact of VS diagnosis or its treatment on QOL.
Granulomatosis with polyangiitis presenting as obstructive uropathy and vasculitic myopathy
Kimbrough, Bradly A. , Naddaf, Elie , Warrington, Kenneth J. , Jiménez, Rafael E. , Naddaf, Elie , Warrington, Kenneth J , Koster, Matthew J.

Mayo Clinic

Rheumatology | September 2, 2022 | Volume: 62 | Issue: 4 | Pages: e136-e137

10.1093/rheumatology/keac506 | PMID 36053184 Get It

Biofilm competency of Desulfovibrio vulgaris Hildenborough facilitates colonization in the gut and represses adenoma development in a rat model of colon cancer
Amos‐Landgraf, James , Busi, Susheel Bhanu , Leόn, Kara De, Montonye, Dan , Wall, Judy D. , Montonye, Dan

Mayo Clinic

No container title available | September 2, 2022 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-1969025/v1 Get It

Abstract Sulfate-reducing bacteria including Desulfovibrio spp. have been associated with suppression of tumor incidence and growth of colorectal cancer (CRC) in human and animal studies. However, other studies suggest that Desulfovibrio spp. are decreased in healthy controls. To address this dichotomy, we treated a rat model of CRC with biofilm-forming and biofilm-deficient strains of Desulfovibrio vulgaris Hildenborough (DvH) to evaluate tumor development. The biofilm-forming DvH stably colonized the rat colon after neonatal administration. Contrarily, the biofilm-deficient strain was undetectable one-week after treatment. The colonic adenoma burden was significantly reduced in the biofilm-forming DvH treated rats compared to the control and biofilm-deficient group. In contrast, known mucin degrading bacteria were increased in the control groups correlating with increased expression of the colonic mucin gene, MUC2, and DNA repair genes MSH2, ATM, and MGMT. This indicates that sulfate reducing biofilm forming bacteria can colonize and protect the colonic epithelium from adenoma initiation.
The Effect of Tobacco Use on the Expression of Placental Transporters in Alaska Native Women
McColl, Eliza R. , Kwok, Jacinda, Benowitz, Neal L. , Hughes, Christine A. , Thomas, Timothy K. , Hiratsuka, Vanessa Y. , Tyndale, Rachel F. , Patten, Christi A. , Tyndale, Rachel F , Hiratsuka, Vanessa , Koller, Kathryn R. , Flanagan, Christie A. , Piquette‐Miller, Micheline

Mayo Clinic

Clinical Pharmacology & Therapeutics | September 2, 2022 | Volume: 113 | Issue: 3 | Pages: 634-642

10.1002/cpt.2737 | PMID 36053152 Get It

Prenatal tobacco use among Alaska Native (AN) women has decreased substantially over the past two decades. Previous research suggests that providing AN women with feedback regarding fetal exposure to tobacco may further promote cessation. Transporters in the placenta regulate fetal exposure to nutrients and xenobiotics, including compounds associated with tobacco use. We examined whether prenatal tobacco use impacts transporter expression in the placenta, and whether this is influenced by fetal sex, degree of tobacco exposure, or transporter genotype. At delivery, we obtained placental samples from AN research participants who smoked cigarettes, used commercial chew or iqmik (oral tobacco), or did not use tobacco during pregnancy. Transporter expression was evaluated using qRT‐PCR and Western blotting and tested for correlations between transcript levels and urinary biomarkers of tobacco use. The impact of BCRP/ABCG2 and OATP2B1/SLCO2B1 genotypes on protein expression was also examined. Oral tobacco use was associated with decreased P‐gp and increased MRP1, MRP3, LAT1, and PMAT mRNA expression. Transcript levels of multiple transporters significantly correlated with tobacco biomarkers in maternal and fetal urine. In women carrying male fetuses, both smoking and oral tobacco were associated with decreased P‐gp. Oral tobacco was also associated with decreased LAT1 in women carrying female fetuses. BCRP and OATP2B1 genotypes did not appear to impact protein expression. In conclusion, prenatal tobacco use is associated with altered expression of multiple placental transporters which differs by fetal sex. As transcript levels of multiple transporters were significantly correlated with tobacco use biomarkers, eliminating prenatal tobacco use should alleviate these changes.
Patient, Physician, Hospital Factors Associated With Readmission After Radical Cystectomy
Mi, Lanyu , Tyson, Mark D. , Faraj, Kassem

Mayo Clinic

Urology Practice | September 2, 2022 | Volume: 9 | Issue: 6 | Pages: 589-595

10.1097/upj.0000000000000345 | PMID 37145810 Get It

Statins and immune checkpoint inhibitors: a strategy to improve the efficacy of immunotherapy for cancer?
Vos, Winnie G. , Lutgens, Esther , Seijkens, Tom T. P.

Mayo Clinic

Journal for ImmunoTherapy of Cancer | September 2, 2022 | Volume: 10 | Issue: 9 | Pages: e005611

10.1136/jitc-2022-005611 Get It

In the past decade, immune checkpoint inhibitor (ICI) therapy significantly improved the prognosis of patients with cancer. Despite impressive and often unprecedented response rates, a significant portion of the patients fails to benefit from this treatment. Additional strategies to improve ICI efficacy are therefore needed. The widespread clinical use of ICIs has increased our knowledge on the effects of the concomitant use of commonly prescribed drugs on the outcome of ICI treatment. A particular interesting class of drugs in this context are statins. These HMG-CoA reductase inhibitors, which are used to treat hypercholesterolemia and reduce the risk for atherosclerotic cardiovascular disease, are frequently used by patients with (advanced) cancer. This paper addresses the hypothesis that statins improve the efficacy of ICI therapy.
Prevention of alcohol-related suicide: a rapid review
Giesbrecht, Norman , Farkouh, Elizabeth K. , Pavalaghanthan, Hariesh, Orpana, Heather , Farkouh, E K

Mayo Clinic

Drugs: Education, Prevention and Policy | September 2, 2022 | Volume: 31 | Issue: 1 | Pages: 1-26

10.1080/09687637.2022.2114877 Get It

Atypical presentations of inclusion body myositis: Clinical characteristics and long‐term outcomes
Alamr, Mazen , Pinto, Marcus Vinícius , Naddaf, Elie , Pinto, Marcus V , Naddaf, Elie

Mayo Clinic

Muscle & Nerve | September 2, 2022 | Volume: 66 | Issue: 6 | Pages: 686-693

10.1002/mus.27716 | PMID 36052422 Get It

AbstractIntroductions/AimsInclusion body myositis (IBM) typically presents with progressive weakness preferentially involving finger flexors and quadriceps. Atypical presentations have been less commonly reported. Here, we aim to describe the clinical characteristics and long‐term outcomes of IBM patients with atypical presentations.MethodsWe retrospectively searched the Mayo Clinic medical records to identify IBM patients with atypical disease onset, seen between 2015 and 2020.ResultsWe identified 357 IBM patients, of whom 50 (14%) had an atypical presentation. Thirty‐eight patients were diagnosed with IBM because they fulfilled one of the European Neuromuscular Center diagnostic categories at a later stage, 10 had all IBM histopathological features, and 2 were diagnosed on the basis of clinical and laboratory data. The most common presentation was dysphagia (50%), followed by asymptomatic hyperCKemia (24%; CK, creatine kinase), then foot drop (12%). 6% of patients presented with proximal arm weakness, 4% with axial weakness and 4% with facial diplegia. Median time from symptom onset to diagnosis was 9 y. Median age at diagnosis was 70.5 y. 16% of patients needed a walking aid. When tested, 86.5% of patients had impaired swallowing and 56% had elevated cytosolic nucleotidase‐1A antibodies. Only 1/26 patients who received immunotherapy had minimal improvement. Upon follow‐up, most patients had generalization of their weakness with a decline in their strength summated score of 0.082/mo.DiscussionA significant proportion of IBM patients may have an atypical presentation. Recognition of such heterogeneity could improve early diagnosis, prevent unnecessary immunotherapy, and provide insight for future diagnostic criteria development and clinical trials.